Front Cover image taken from page 1291, figure 2 of Bulirsch L, et al. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. The figure shows an exemplary case of a patient with subretinal fluid at baseline (BSL) (D) and both intraretinal and subretinal fluid 1 (C), 3 (B) and 6 (A) months in historical imaging before baseline despite regular anti-vascular endothelial growth factor treatment as demonstrated in (from left to right) near-infrared imaging, spectral-domain optical coherence tomography through the fovea and colour-coded two-dimensional thickness map for total retinal thickness.